AstraZeneca to pay
.52 million to
resolve SEC
foreign bribery case
(Reuters) - U.S. regulators said on Tuesday that
AstraZeneca Plc will pay
.52 million to
resolve a
foreign bribery probe into improper payments by its sales and marketing staff to state-employed healthcare officials in China and Russia.